Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow (Nasdaq: HROW) announced FDA clearance of an IND to support a planned Phase 3 trial of TRIESENCE 40 mg/mL for ocular inflammation and pain following cataract surgery. The randomized, placebo-controlled, double-masked study will enroll ~250 patients (2:1 randomization) with primary endpoints at Day 14 (anterior chamber cells) and Day 8 (pain).
Harrow expects study initiation in Q1 2026 and enrollment to start in Q2 2026, aiming to generate data to potentially expand TRIESENCE’s label and strengthen its surgical care role.
Harrow (Nasdaq: HROW) reported record Q4 revenue of $89.1M (up 33% YoY) and full-year 2025 revenue of $272.3M (up 36% YoY). GAAP net income was $6.6M in Q4 while full-year GAAP showed a $5.1M net loss. Adjusted EBITDA was $24.2M in Q4 and $61.9M for 2025. Harrow generated $43.9M operating cash flow in 2025 and ended the year with $72.9M cash. 2026 guidance: revenue $350M–$365M and Adjusted EBITDA $80M–$100M.
Harrow (Nasdaq: HROW) will report fourth quarter and year-end 2025 financial results on March 2, 2026 after market close and will post a Q4 Letter to Stockholders on its Investors webpage.
The company will host a conference call and live webcast at 8:00 a.m. ET on March 3, 2026, with a replay available on the website for one year.
Harrow (Nasdaq: HROW) launched PharmaPack, a Direct-to-Prescriber cash-pay program on Feb 17, 2026, offering FDA-approved ophthalmic kits as affordable alternatives to compounded products.
Initial availability covers California, Mississippi, Arkansas, Connecticut, and Alabama, with nationwide expansion planned in the coming weeks.
OSRX (HROW) confirmed it remains fully licensed, FDA-registered and operational in California and all 50 states following a competitor's market exit.
According to the company, ImprimisRx voluntarily forfeited its California license on Feb 1, 2026 and agreed to pay an administrative fine of approximately $157,000 to the California Board of Pharmacy. OSRX says it supports thousands of ophthalmologists and optometrists and offers direct-to-patient and direct-to-facility dispensing of compounded ophthalmic medications.
Harrow (Nasdaq: HROW) reaffirmed full-year 2025 revenue guidance of $270–$280 million and announced operational expansions: doubling the VEVYE sales force by Memorial Day 2026, doubling the surgical sales force for TRIESENCE, and expanding IHEEZO into office-based procedures (estimated >2.5 million annual use cases).
The company is on track to file NDAs for MELT-300 and MELT-210 in H1 2027, launched the OneHarrow branding initiative, promoted Patrick W. Sullivan to Chief Commercial Officer, and ImprimisRx settled California regulatory matters with a ~$157,000 fine and exited California effective Feb 1, 2026.
Harrow (Nasdaq: HROW) announced management will present at two investor conferences in December 2025.
Events and formats:
- BTIG 5th Annual Ophthalmology Day (virtual) — fireside chat on Monday, December 1, 2025 at 8:30 AM ET.
- Piper Sandler 37th Annual Healthcare Conference (New York, NY) — fireside chat on Tuesday, December 2, 2025 at 3:00 PM ET. The Piper Sandler talk will be webcast live on the company website and a replay will be available for approximately 90 days.
Harrow (Nasdaq: HROW) closed the acquisition of Melt Pharmaceuticals, adding clinical-stage candidates MELT-210, MELT-300, and MELT-400 based on a Zydis oral-dissolving tablet platform.
MELT-300 is a sublingual fixed-dose midazolam (3mg) + ketamine (50mg) formulation that completed Phase 2 and Phase 3 programs with stated statistical superiority to midazolam alone. Harrow plans one non-clinical and three PK studies to complete an NDA filing in H1 2027, regulatory review targeting H1 2028, and commercial launch in H2 2028. Harrow cites >800 U.S. ophthalmic institutions using its MKO Melt compounded product as a commercial foothold.
Harrow (Nasdaq: HROW) reported Q3 2025 total revenues of $71.6 million, a 45% increase versus $49.3 million in Q3 2024, and adjusted EBITDA of $22.7 million. GAAP net income for the quarter was $1.0 million and cash and cash equivalents were $74.3 million as of September 30, 2025.
Operational highlights include new national payer coverage agreements for VEVYE effective January 1, 2026, expansion of the VEVYE Access For All program via a partnership with Alto Pharmacy Powered by Fuze Health, the launch of Harrow Access for All (HAFA), and an agreement to acquire Melt Pharmaceuticals, maker of MELT-300.
Harrow (Nasdaq: HROW) will report third quarter 2025 financial results for the period ended September 30, 2025, on Monday, November 10, 2025 after market close. The company said it will post a Third Quarter Letter to Stockholders on its Investors page at harrow.com.
Harrow will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 11, 2025 to discuss results and provide a business update. A replay will be available on the company website for one year. Telephone participants must register in advance to receive a unique dial-in and PIN.